Insulin Delivery Devices Market Report Size Analysis:

The insulin delivery devices market size was valued at USD 17.73 billion in 2024 and is expected to reach USD 32.57 billion by 2032, growing at a CAGR of 7.92% over the forecast period of 2025-2032.

The insulin delivery devices market size is growing due to a high incidence rate of diabetes mellitus around the world, technological advancements, and increasing patient awareness in diabetes management. The prevalence of diabetes has been estimated to have affected 537 million adults in 2021 and is expected to reach 643 million by 2030 (IDF). This increasing burden is driving the need for more convenient delivery systems, such as insulin pens, pumps, and AID systems. Moreover, advancements including tubeless insulin pumps and closed-loop systems, and increasing acceptance of wearable technology are some factors creating demand for the insulin delivery devices market.

A March 2025 NEJM Evidence report emphasized favorable results of advanced automated insulin delivery systems, with enhanced glycemic control in adolescents, contributing to provider receptivity.

Market acceleration is compounded by regulatory support provided by newly updated Endocrine Society guidelines and growing FDA approvals for digital insulin delivery technologies. Escalating R&D funding in the form of smart insulin and AI-incorporated delivery platforms, along with favorable reimbursement policies for the best part of the U.S. and Europe, is also shaping the market landscape. More than 30% of people with type 1 diabetes in the U.S. are currently on a pump, so there is a definite move toward these devices for insulin therapy. Increasing healthcare expenditure and public-private partnerships to improve supply chains and access to devices, led to opportunities in the insulin delivery devices market size and forecast.

For instance, Medtronic and Insulet Corporation, two players in the insulin delivery devices market, introduced AI-based insulin pump technologies that enable personalized insulin delivery, a testament to the continued expansion and innovation in the global insulin delivery devices market.

Insulin Delivery Devices Market Dynamics:

Drivers:

• Innovations, Rising Prevalence, and Regulatory Advancements Fueling the Market Growth

The insulin delivery devices market is pushed by increasing diabetes population, technological advancements, and changes in clinical guidelines. Between 2021 and 2045, the global diabetes population will grow by almost 51%, leading to a sustained need for effective insulin delivery modalities.

Rising use of smart insulin pens and patch pumps, such as the wearable "CeQur Simplicity", is boosting patient adherence. In a 2024 article in Clinical Diabetes, insulin pen use grew by 35% between 2018 and 2023 due to ease and accuracy gains. Moreover, the increasing geriatric population, which is generally prone to type 2 diabetes, is widening the user base. Both the FDA and EMA have recently approved a variety of next-generation insulin delivery solutions, facilitating the route to market access for new technologies.

R&D investments are also on the rise, with companies such as Novo Nordisk and Tandem Diabetes Care committing more than 12% of their revenue to device innovation, fueling the growth of the market. Collaborations between med-tech companies and AI vendors have driven progress in closed-loop systems. The global insulin delivery devices market share will continue to expand as new Thing reimbursement models to the form in the U.S. and Europe, and supply chain improvements AND increased manufacturing investments make these technologies more widely available.

Restraints:

• High Costs, Technological Barriers, and User Education Limit Adoption, also Hinder Market Expansion

The high out-of-pocket cost of more advanced devices, such as insulin pumps and continuous glucose monitoring (CGM) systems, acts as a deterrent, especially among middle-income and uninsured individuals. A study in the JMCP in 2024 found that more than 40% of diabetes patients in the U.S. reported that cost was a barrier to their use of more modern insulin delivery systems. Complex device interfaces and care needs can also become barriers, particularly for older patients or those with lower levels of health literacy. In addition, variations in technology between locations may lead to unequal equipment distribution and supply chain disruptions.

Regulatory and reimbursement challenges still exist; for instance, while the U.S. has had some success in securing CMS coverage for insulin pumps, many other markets have little to no coverage policies, which in turn limit device penetration. Furthermore, inadequate physician training and patient education lead to poor use and compliance. Another study, which is PubMed-indexed, reveals that more than 25% of the patients terminate insulin pump therapy within the first year for reasons of problems with device manipulation and side effects. These issues, along with slow innovation approvals in certain territories, restrict the market share of insulin delivery devices and make the effectiveness of life-changing technologies less powerful. Continued focus on affordability, availability, and awareness is important to sustain the insulin delivery devices market growth.

Insulin Delivery Devices Market Segmentation Analysis:

By Product

In 2024, insulin pens held the largest share of the insulin delivery systems market by product, with a share of 48.6%. They are popular as they are simple, portable, requiring less training in use, with less tendency to dosing errors, and thus preferred by the patients and more so by those who control Type 2 diabetes. Pre-load features and ease of use increase patient adherence and convenience. Additionally, the rise in several connected smart insulin pens has expanded acceptance in developed and developing markets.

Insulin pumps are expected to be the fastest-growing product type during the forecast period. The insulin delivery systems market growth is driven by increasing awareness about the benefits of intensive insulin therapy, technological advancements in automated insulin delivery devices, and increasing reimbursement for CGM devices in Type 2 diabetes patients. The rise of tubeless systems and wearable pumps, such as patch pumps, and the increasing integration with CGM, have played a key role in this trend, especially among younger and technology crowds.

By End Use

The homecare application dominated the insulin delivery devices market in 2024 and accounted for 52.2% of the value. The growing preference for diabetes self-management and increased penetration of user-friendly insulin delivery devices and remote patient monitoring tools are mainly responsible for the larger share of this segment. There is yet another driver of home-based care: it cuts costs and hospital visits, which is turning out to be more and more palatable to insurers and patients.

The hospitals and clinics department segment is projected to witness the fastest growth. Such growth is due to the growing volume of diabetes related hospital admissions, improvements to in-hospital insulin delivery processes, and the rising prominence of hospital-based diabetes education programs. Better healthcare infrastructure and early detection campaigns, and advanced insulin devices in institutional care are also assisting in the fast growth of this segment.

Regional Analysis:

Based on region, North America contributed the highest share, holding 45.2% in 2024, and is estimated to dominate in terms of revenue share during the forecast period, owing to the higher prevalence of diabetes, robust healthcare infrastructure, and reimbursement. The U.S. insulin delivery devices market size was valued at USD 6.06 billion in 2024 and is expected to reach USD 9.91 billion by 2032, growing at a CAGR of 6.40% over the forecast period of 2025-2032, due to the early adoption of advanced technology, an increasing awareness level of diabetes, and a large population using insulin pumps. More than 37 million people in the U.S. have diabetes, driving ongoing demand for new insulin delivery options, the CDC reports. Strong regional market presence is augmented by the presence of key players, including Medtronic and Insulet.

The Canada insulin delivery devices market is also growing on account of elevating Type 1 diabetes occurrence along with the increased availability of advanced insulin delivery devices under the government health programs. Mexico is growing with more government initiatives to address diabetes and increased access to healthcare, though affordability and education are obstacles in rural areas.

Europe is a developed insulin delivery devices market with organized diabetes care programs, well-defined national diabetes management guidelines, and national and regional policies reducing out-of-pocket expenditure. Germany is the leader in the region owing to a robust public health system, a large population of diabetics, and early penetration of insulin pump treatment. The U.K./France market is enjoying strong penetration of wearable insulin technologies, thanks to their progressive health policies. Mentioning also that Germany has more than 8,500,000 diabetics in 2023 (a very big demand pool). Poland and Turkey are experiencing rapid growth in the use of insulin pens driven by government reimbursement and more patient education. The second-fastest growing area after Asia Pacific, Europe is prioritizing digital health and telemonitoring, driving the use of devices outside healthcare facilities.

Asia Pacific insulin delivery devices market is the fastest growing region owing to the presence of the largest diabetic population globally, especially in India and China, and increasing healthcare expenditures and awareness. China prevails due to its enormous diabetic population (more than 140 million in 2023), rapid urbanization, and policy-led diabetes screening initiatives. The Indian market is growing by leaps and bounds due to the increasing young diabetic population, also owing to the easy availability of insulin pens, and local production of the devices at lower costs. Autonomous systems have been adopted in Japan and South Korea as well, stimulated by the environment with a well-developed health technology ecosystem.

The LAMEA region is growing at a steady pace, limited by deficiencies in infrastructure and affordability. Brazil is the largest market in Latin America, driven by government diabetes programs and a burgeoning private health system, and Argentina is experiencing higher insulin pump uptake thanks to expanding insurance coverage. In the Middle East, Saudi Arabia is top of the table on account of its high diabetes burden (nearly 18% of the population), and state-led health reforms under Vision 2030.

Insulin Delivery Devices Market Key Players:

Leading insulin delivery devices companies operating in the market comprise Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Ypsomed AG, Medtronic, Insulet Corporation, B. Braun SE, Owen Mumford Ltd., Tandem Diabetes Care, Inc., and BD (Becton, Dickinson, and Company).

Recent Developments in the Insulin Delivery Devices Market:

In May 2025, CeQur Simplicity obtained FDA clearance for 4-day wearable mealtime insulin delivery, simplifying diabetes management with extended wearability.

In April 2025, Embecta received FDA clearance for a next-generation insulin delivery system, supporting innovation in user-centric therapy options.